



October 31, 2012

## Astex Pharmaceuticals to Present at EORTC-NCI-AACR

DUBLIN, Calif., Oct. 31, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced the acceptance of three abstracts for presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Poster presentations will occur Nov 7 — 9 in Dublin, Ireland.

<b>XIAP</b>	Abstract #85, Poster Board #052	
Poster Presentation:	Wednesday, Nov 7, 2012	12:00 — 2:15 pm GMT
Characterization of a potent XIAP and cIAP1 dual antagonist in models of melanoma and leukemia		
<b>AT13387</b>	Abstract #293, Poster Board #043	
Poster Presentation:	Thursday, Nov 8, 2012	12:00 — 2:15 pm GMT
Activity of the HSP90 inhibitor, AT13387, in ALK-driven tumor models		
<b>SGI-110</b>	Abstract #465, Poster Board #036	
Poster Presentation	Friday, Nov 9, 2012	8:30 — 10:30 am GMT
SGI-110, a novel second generation DNA hypomethylating agent, enhances sorafenib activity and alters methylation signature of HCC cell lines		

Select posters will be made available for viewing on the company's website <http://astx.com/pipeline/publications/> following the public presentation.

### About Astex Pharmaceuticals

Astex Pharmaceuticals is dedicated to the discovery and development of novel small molecule therapeutics with a focus on oncology. The Company is developing a proprietary pipeline of novel therapies and is creating de-risked products for partnership with leading pharmaceutical companies. Astex Pharmaceuticals developed DACOGEN® (decitabine) for Injection and receives significant royalties on global sales.

For more information about Astex Pharmaceuticals, Inc., please visit <http://www.astx.com>.

The Astex Pharmaceuticals, Inc. logo is available at <http://www.globenewswire.com/newsroom/prs/?pkgid=12273>

CONTACT: Timothy L. Enns

Astex Pharmaceuticals, Inc.

Senior Vice President

Corporate Communications & Marketing

Tel: +1 (925) 560-2810

E-mail: [tim.enns@astx.com](mailto:tim.enns@astx.com)

Alan Roemer

The Trout Group

Managing Director

Tel: +1 (646) 378-2945

E-mail: aroemer@troutgroup.com

Susanna Chau

Astex Pharmaceuticals, Inc.

Manager

Investor Relations

Tel: +1 (925) 560-2845

E-mail: susanna.chau@astx.com

Kari Watson

MacDougall Biomedical Communications

Senior Vice President

Tel: +1 (781) 235-3060

E-mail: kwatson@macbiocom.com